Japanese firm Hisamitsu Pharmaceutical Co. Inc. has offered to buy Noven Pharmaceuticals Inc. for about $428 million in a move that would combine transdermal drug delivery technologies of both firms and expand Hisamitsu's presence in the U.S. (BioWorld Today) Read More
